Description
Tirzide 7.5 MG (Tirzepatide) is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist the world’s first and only approved twincretin supplied as a 7.5 mg solution for injection in a pre-filled syringe (1 syringe/box with alcohol pad and first aid bandage) and manufactured by Everest Pharmaceuticals Ltd. in Bangladesh. Its active ingredient, tirzepatide, simultaneously engages both the GIP receptor and the GLP-1 receptor with a single weekly subcutaneous injection, producing glycemic and cardiometabolic outcomes superior to those of all approved selective GLP-1 receptor agonists.
The 7.5 mg dose of tirzepatide is the second maintenance dose in the reference-label six-step titration schedule prescribed after a minimum of four weeks at the first maintenance dose of 5 mg when additional glycemic or weight management control is required, and positioned as the precisely calibrated intermediate step between the 5 mg first maintenance level and the 10 mg dose, the next pivotal efficacy level evaluated in the SURPASS Phase 3 programme. The SURPASS Phase 3 programme established a clear and consistent dose-response relationship across all evaluated tirzepatide doses: in SURPASS-2 (n=1,879 adults with type 2 diabetes mellitus), moving from tirzepatide 5 mg to 10 mg produced an incremental HbA1c reduction of 0.23 percentage points (from –2.01% to –2.24%) and an incremental body weight reduction of 1.7 kg (from –7.6 kg to –9.3 kg) versus semaglutide 1 mg at 40 weeks, with every dose step delivering progressively superior glycemic control and weight reduction.
The 7.5 mg dose is clinically designed to capture meaningful incremental dual GIP/GLP-1 receptor occupancy and therapeutic benefit beyond 5 mg while minimising the gastrointestinal burden of a direct 5 mg-to-10 mg jump the defining pharmacological rationale for graduated 2.5 mg step titration that the tirzepatide prescribing programme uniquely provides. Searching for Tirzide 7.5 MG Tirzepatide? Mediaid Pharmacy lists this product within its comprehensive diabetes medicines portfolio and ships it worldwide.
Basic Product Information of Tirzide 7.5 MG (Tirzepatide)
| Brand Name | Tirzide 7.5 MG (Tirzepatide) |
| Product Name | Tirzide |
| Generic Name | Tirzepatide INN |
| Drug Class | Dual GIP (Glucose-Dependent Insulinotropic Polypeptide) and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonist; Twincretin; Antidiabetic Agent; Incretin-Based Therapy |
| Formulation | Solution for Injection (Pre-filled Syringe) |
| Available Strength | 7.5 mg |
| Available Pack Size | 1 Pre-filled Syringe/Box (with alcohol pad & first aid bandage) |
| Dose Position & Primary Indications | Second maintenance dose in the six-step tirzepatide titration schedule. Type 2 diabetes mellitus (T2DM) in adults as an adjunct to diet and exercise: prescribed as 7.5 mg subcutaneously once weekly for ≥4 weeks after completing ≥4 weeks at 5 mg when additional glycemic control is required; may titrate further to 10 mg after ≥4 weeks at 7.5 mg if needed. Chronic weight management in adults with initial BMI ≥30 kg/m² (obesity) or ≥27 kg/m² (overweight) with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity: same 7.5 mg second maintenance dose and titration schedule applies. Patients who achieve their individualised glycemic or weight management target at 7.5 mg once weekly may remain at this dose as a long-term maintenance level without mandatory further titration to 10 mg. Maximum dose across all indications: 15 mg once weekly. |
| Manufacturer | Everest Pharmaceuticals Ltd., Bangladesh |
| Registration | Bangladesh |
| Originator Reference Brand | Mounjaro (tirzepatide) by Eli Lilly for type 2 diabetes; Zepbound (tirzepatide) by Eli Lilly for chronic weight management |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Storage Conditions | Store at 2°C to 8°C (refrigerated). Do not freeze. Protect from light. If stored at room temperature (up to 30°C/86°F), use within the period stated on the pack. Keep out of the reach of children. |
How Tirzide 7.5 MG (Tirzepatide) Works: Incremental Dual Receptor Occupancy at the Second Maintenance Level
Tirzepatide, the active ingredient in Tirzide 7.5 MG, is the world’s first approved dual GIP and GLP-1 receptor agonist the twincretin drug class defined by simultaneous pharmacological activation of two endogenous incretin hormone receptors within a single weekly subcutaneous injection. At the 7.5 mg dose, tirzepatide delivers a measurably higher degree of dual receptor occupancy at both the GIP receptor and the GLP-1 receptor compared with the 5 mg first maintenance dose, translating into incrementally greater pharmacodynamic effects deeper glucose-dependent insulin secretion, more sustained glucagon suppression, more pronounced central appetite inhibition, and broader adipose tissue lipid metabolism modulation than are achieved at the 5 mg level.
Understanding the pharmacological role of the 7.5 mg dose requires understanding the receptor-occupancy pharmacology of tirzepatide: like all receptor agonists operating on a hyperbolic concentration-response curve, tirzepatide’s pharmacodynamic intensity increases proportionally with plasma concentration across the lower segments of the dose-response curve, meaning that each 2.5 mg step increase from 5 mg to 7.5 mg and from 7.5 mg to 10 mg provides a predictable, proportionally distributed fraction of the total pharmacodynamic range achievable between the minimum effective maintenance dose (5 mg) and the maximum approved dose (15 mg).
The structured 2.5 mg step-titration schedule of the tirzepatide reference prescribing information moving from 5 mg to 7.5 mg to 10 mg to 12.5 mg to 15 mg at four-week intervals is specifically designed to follow this pharmacokinetic gradient, allowing each dose increment to reach pharmacokinetic steady-state (approximately 4 to 5 half-lives, or 4 to 5 weeks at the approximately 5-day half-life of tirzepatide) before the prescriber and patient assess glycemic response and tolerability and decide whether to proceed to the next increment.
At the 7.5 mg maintenance dose, tirzepatide’s GLP-1 receptor agonism operates across all four established antidiabetic mechanisms with greater receptor engagement than at 5 mg: (1) amplified glucose-dependent beta-cell insulin secretion the GLP-1 receptor-coupled adenylyl cyclase-cAMP-PKA cascade in pancreatic beta-cells is activated at higher receptor occupancy, producing proportionally greater postprandial insulin release per glucose stimulus; (2) deeper glucose-dependent suppression of pancreatic alpha-cell glucagon secretion, further reducing hepatic glucose output and lowering fasting plasma glucose; (3) sustained prolongation of gastric emptying delay beyond the 5 mg level, extending the duration over which postprandial carbohydrates are absorbed and blunting postprandial glucose excursions; and (4) more sustained hypothalamic and brainstem GLP-1 receptor-mediated anorexigenic signalling, producing greater reduction in meal size and total caloric intake.
Tirzepatide’s GIP receptor agonism at 7.5 mg provides additional incremental contributions: increased GIP receptor-coupled cAMP-PKA activation in pancreatic beta-cells amplifies the already enhanced GLP-1-mediated insulin secretagogue effect through a parallel non-redundant signalling pathway, while greater GIP receptor engagement in adipose tissue supports more extensive lipoprotein lipase-mediated triglyceride clearance and fatty acid re-esterification, contributing to the progressive reduction in visceral and hepatic fat content observed across the tirzepatide dose range in imaging substudies of the SURPASS programme. Clinicians building comprehensive diabetes management programmes can review the full range of tirzepatide medicines at Mediaid Pharmacy, including the complete Tirzide strength range available for worldwide delivery.
The critical pharmacological rationale for the 7.5 mg intermediate dose rather than a direct jump from 5 mg to 10 mg is the graduated gastrointestinal tolerability management that 2.5 mg step titration uniquely provides. Gastrointestinal adverse events (nausea, vomiting, diarrhoea, and constipation) are the most common reason for tirzepatide dose reduction or discontinuation, and their frequency and severity are dose-dependent: moving directly from 5 mg to 10 mg doubles the dose increment and produces a more abrupt increase in gastric emptying delay and central appetite suppression than does the 2.5 mg step from 5 mg to 7.5 mg.
The prescribing programme’s four intermediate doses (7.5 mg, 10 mg, 12.5 mg) between the first maintenance level (5 mg) and the maximum dose (15 mg) are each separated by a 2.5 mg increment to ensure that every 4-week adaptation window at each dose level is proportional to the magnitude of the receptor engagement increase, minimising peak GI adverse event burden and protecting long-term adherence through the full titration course. The SURPASS Phase 3 programme demonstrated a consistent and statistically significant dose-response relationship for both HbA1c reduction and body weight loss across the 5 mg, 10 mg, and 15 mg evaluated doses: in SURPASS-2 (n=1,879), the 5 mg → 10 mg step delivered an incremental HbA1c improvement of 0.23 percentage points (–2.01% to –2.24%) and an incremental weight reduction of 1.7 kg (–7.6 kg to –9.3 kg), with the 10 mg → 15 mg step producing a further 0.06 percentage point HbA1c gain and 1.9 kg additional weight loss confirming that meaningful dose-dependent incremental gains are distributed across the full titration range and are mechanistically accessible through the 7.5 mg intermediate step. Prescribers sourcing the full Tirzide strength range for their clinical programmes can contact Mediaid Pharmacy through the diabetes medicines portfolio page for consolidated supply and pricing.
Tirzide 7.5 MG delivers the 7.5 mg second maintenance dose of tirzepatide in a ready-to-inject pre-filled syringe requiring no reconstitution, dose calculation, or device dialling the patient or caregiver injects the entire syringe contents subcutaneously once weekly into the abdomen, thigh, or upper arm. Each box contains 1 pre-filled syringe with an alcohol pad and first aid bandage, providing a complete one-week injection kit. At the 7.5 mg dose, tirzepatide achieves pharmacokinetic steady-state within 4 to 5 weeks of weekly dosing the same timeline as at all other tirzepatide dose levels, based on the approximately 5-day plasma half-life achieved through tirzepatide’s fatty acid conjugation and albumin-binding engineering after which a stable and reproducible plasma concentration-time profile is established that supports assessment of glycemic response and GI tolerability before any further dose escalation decision is made.
Approved Indications and Dose Position of Tirzepatide 7.5 MG (Reference Label for Tirzide 7.5 MG (Tirzepatide))
Tirzepatide, the active ingredient in Tirzide 7.5 MG, is approved across two therapeutic areas type 2 diabetes mellitus glycemic management and chronic weight management with the 7.5 mg dose holding a uniquely defined dual role in both indications: it is simultaneously the second maintenance dose that patients escalate to from 5 mg when additional glycemic or weight control is needed, and a permissible long-term maintenance dose for patients who achieve their treatment targets without requiring titration to 10 mg or above.
The reference prescribing information does not mandate further titration beyond 7.5 mg for patients at goal an important prescribing flexibility that allows clinicians to individualise the maintenance dose to the minimum effective level for each patient, reducing unnecessary GI adverse event exposure from higher doses. Prescribers should confirm locally approved indications on the Tirzide product label and applicable national diabetes and obesity clinical guidelines before prescribing Tirzide 7.5 MG.
|
Type 2 Diabetes Mellitus Second Maintenance Dose When 5 mg Does Not Achieve Glycaemic Target Indicated for adults with T2DM as an adjunct to diet and exercise: prescribed at 7.5 mg subcutaneously once weekly for ≥4 weeks after ≥4 weeks at 5 mg when HbA1c or fasting plasma glucose targets are not met at the 5 mg first maintenance level. The SURPASS Phase 3 programme established a clear dose-dependent pattern: in SURPASS-2, moving from 5 mg to 10 mg produced an incremental HbA1c improvement of 0.23 percentage points (–2.01% to –2.24%) and 1.7 kg additional weight reduction (–7.6 kg to –9.3 kg) at 40 weeks versus semaglutide 1 mg. The 7.5 mg dose occupies the pharmacodynamic midpoint of this increment, accessing intermediate receptor occupancy and glycaemic benefit that is pharmacokinetically proportional to the 2.5 mg dose step. Patients achieving glycaemic targets at 7.5 mg may remain at this dose without further titration. For additional antidiabetic agents, browse the diabetes medicines collection at Mediaid Pharmacy. |
Chronic Weight Management 7.5 mg Second Maintenance Dose for Progressive Weight Reduction Beyond 5 mg Indicated for chronic weight management in adults with BMI ≥30 kg/m² (obesity) or ≥27 kg/m² (overweight) with at least one weight-related comorbidity (hypertension, dyslipidemia, T2DM, obstructive sleep apnea, or cardiovascular disease), as an adjunct to a reduced-calorie diet and increased physical activity: prescribed at 7.5 mg once weekly for ≥4 weeks after the 5 mg first maintenance phase when additional weight reduction is needed. The SURMOUNT-1 programme demonstrated consistent dose-dependent weight loss across 5 mg (–15.0%), 10 mg (–19.5%), and 15 mg (–22.5%) at 72 weeks, with each dose step delivering incrementally greater weight reduction the 7.5 mg dose is positioned to access the intermediate weight-loss increment between 5 mg and 10 mg. Patients achieving weight management goals at 7.5 mg may remain at this dose. For the complete tirzepatide strength range, visit the tirzepatide medicines collection at Mediaid Pharmacy. |
Key Clinical Benefits of Tirzide 7.5 MG (Tirzepatide)
|
Incremental Dose-Dependent HbA1c and Weight Improvement Through Calibrated Second-Step Receptor Escalation The SURPASS Phase 3 programme demonstrated that each successive tirzepatide dose step from 5 mg to 10 mg to 15 mg delivers statistically significant incremental improvements in both HbA1c reduction and body weight loss. In SURPASS-2 (vs. semaglutide 1 mg, n=1,879, 40 weeks), the 5-to-10 mg step produced an incremental HbA1c gain of 0.23 percentage points and 1.7 kg additional weight loss; in SURPASS-1 (vs. placebo, n=478, 40 weeks), the same step produced an incremental HbA1c gain of 0.02 percentage points and 0.8 kg additional weight reduction. The 7.5 mg dose, as the pharmacokinetically proportional intermediate between 5 mg and 10 mg, captures half of this inter-dose efficacy increment through proportional increases in dual GIP and GLP-1 receptor occupancy providing clinically meaningful additional glycaemic and metabolic benefit for patients whose HbA1c or weight remains above target after ≥4 weeks at 5 mg, without requiring a full 5-to-10 mg dose doubling that may intensify GI adverse events before the GI tract has fully adapted to the first maintenance level. |
Reduced Gastrointestinal Adverse Event Risk Through Graduated 2.5 mg Step-Up Between Maintenance Levels Nausea, vomiting, diarrhoea, and constipation are the most dose-dependent adverse effects of tirzepatide and the primary driver of early treatment discontinuation across the GLP-1 receptor agonist and twincretin class. The six-step 2.5 mg titration schedule of the tirzepatide prescribing programme including the 7.5 mg intermediate step between 5 mg and 10 mg is specifically designed to minimise peak GI adverse event intensity at each transition by limiting the magnitude of each dose increment. Moving from 5 mg to 7.5 mg represents a 50% dose increase from the first maintenance level, compared with the 100% dose increase of a direct 5-to-10 mg jump: the smaller increment produces a more gradual increase in gastric emptying delay and central appetite suppression, allowing the GI tract additional adaptation time before the full 10 mg exposure level is reached. For patients with moderate GI sensitivity or a history of GI adverse events on GLP-1 receptor agonists, the 7.5 mg intermediate step is particularly clinically valuable in protecting long-term adherence to the tirzepatide programme. |
Validated Long-Term Maintenance Dose Remain at 7.5 mg or Continue to 10 mg Based on Individual Target Achievement Tirzepatide 7.5 mg once weekly is a reference-label-approved long-term maintenance dose not merely a transitional titration step meaning that patients who achieve their individualised HbA1c (typically below 7.0% per ADA/EASD guidelines) or weight management target after ≥4 weeks at 7.5 mg may remain at this dose indefinitely without mandatory further escalation to 10 mg. This prescribing flexibility allows endocrinologists and diabetologists to identify the minimum effective maintenance dose for each patient, balancing glycaemic and weight management efficacy against GI tolerability burden, and to maintain patients at the lowest dose at which targets are durably sustained. Tirzide 7.5 MG is supplied in the same once-weekly pre-filled syringe format as every other Tirzide strength requiring no reconstitution, pen dialling, or dose calculation ensuring consistent, simple injection technique regardless of which maintenance dose level the patient occupies in their personalised titration programme. |
Drug Interactions and Important Safety Information for Tirzide 7.5 MG (Tirzepatide)
At the 7.5 mg second maintenance dose, tirzepatide’s pharmacodynamic drug interaction profile is qualitatively identical to that at the 5 mg first maintenance level the same receptor mechanisms and metabolic pathways operate but with quantitatively greater pharmacological intensity at both the GIP receptor and the GLP-1 receptor, meaning that all dose-dependent pharmacodynamic interactions are proportionally more pronounced at 7.5 mg than at 5 mg. The most clinically significant interaction categories for tirzepatide 7.5 mg are insulin and insulin secretagogues, orally administered narrow-therapeutic-index medications with absorption-rate sensitivity, and agents that independently modulate glycaemic control. Tirzepatide’s elimination pathway proteolytic degradation of its peptide backbone at multiple sites and beta-oxidation/omega-oxidation of its C18 fatty acid side chain is entirely CYP enzyme-independent, confirming that Tirzide 7.5 MG carries no clinically relevant CYP3A4, CYP2C9, CYP2D6, or other major CYP isoform drug-drug interactions.
Insulin and insulin secretagogues are the highest-priority pharmacodynamic interaction partners at 7.5 mg. The transition from 5 mg to 7.5 mg increases tirzepatide’s glucose-dependent insulin secretagogue effect at both the GIP receptor and the GLP-1 receptor a pharmacodynamic intensification that increases the risk of hypoglycaemia in patients simultaneously receiving basal insulin (insulin glargine, insulin degludec, insulin detemir), prandial insulin, pre-mixed insulin formulations, or fixed-ratio insulin/GLP-1 combination products. Prescribers should reassess the concomitant insulin dose when escalating from tirzepatide 5 mg to 7.5 mg, and self-monitoring of blood glucose should be intensified during the 4-week period following each dose escalation step.
Sulfonylureas (glibenclamide, glipizide, glimepiride, gliclazide) and meglitinides (repaglinide, nateglinide) carry an analogous pharmacodynamic hypoglycaemia risk through their glucose-independent pancreatic insulin-releasing mechanism; dose reduction of the sulfonylurea or meglitinide should be re-evaluated at the time of escalation to 7.5 mg, not only at tirzepatide initiation. Oral medications sensitive to absorption rate including oral hormonal contraceptives, levothyroxine, warfarin, and orally administered narrow-index antibiotics require the same management at 7.5 mg as at all other tirzepatide maintenance doses: women using oral hormonal contraceptives should add a barrier method for 4 weeks after the dose escalation to 7.5 mg; levothyroxine-treated patients should have TSH measured 6 to 8 weeks after the escalation; and INR should be monitored more frequently when dose escalation occurs in anticoagulated patients. Clinicians sourcing companion antidiabetic and cardiometabolic agents alongside Tirzide 7.5 MG can explore the full diabetes medicines range available at Mediaid Pharmacy with worldwide shipping.
Corticosteroids (systemic, intra-articular, epidural, or high-potency topical) antagonise tirzepatide’s glycaemic effect at 7.5 mg by inducing insulin resistance and hepatic glucose output in a dose- and duration-dependent manner; blood glucose monitoring must be intensified and temporary antidiabetic dose adjustments made whenever corticosteroid therapy is started, modified, or stopped in patients on Tirzide 7.5 MG. Alcohol increases hypoglycaemia risk in patients receiving concurrent insulin or sulfonylurea, and patients should be clearly counselled to limit alcohol intake throughout tirzepatide maintenance.
Atypical antipsychotics with metabolic effects (olanzapine, clozapine, quetiapine, risperidone) may partially counteract tirzepatide’s glycaemic and weight management effects through insulin resistance induction and appetite dysregulation; this combination warrants closer glycaemic monitoring and individualised dose titration planning by the endocrinology team. Sympathomimetic agents (epinephrine, pseudoephedrine, albuterol, and related agents) transiently elevate blood glucose by stimulating glycogenolysis and inhibiting insulin secretion through alpha-adrenergic pathways, partially attenuating tirzepatide’s glycaemic effect; monitoring intensification is required during acute sympathomimetic use in tirzepatide-treated patients. Patients must disclose all medications prescription, over-the-counter, nutritional supplements, and herbal products to their prescribing endocrinologist or diabetologist before and throughout Tirzide 7.5 MG treatment. Providers seeking Everest Pharmaceuticals-branded companion medicines alongside Tirzide 7.5 MG can browse the Everest Pharmaceuticals medicines range at Mediaid Pharmacy.
Side Effects and Precautions of Tirzide 7.5 MG (Tirzepatide)
|
Common Side Effects Nausea (most frequently reported adverse event at the 7.5 mg second maintenance dose; more pronounced at 7.5 mg than at 5 mg due to increased GLP-1 receptor-mediated gastric emptying delay; the 4-week 5 mg adaptation period substantially mitigates the severity of nausea experienced at the transition to 7.5 mg compared with patients titrated more rapidly; eating smaller, lower-fat meals and avoiding eating immediately before injection reduces intensity) Diarrhoea (dose-dependent GI adverse event; may intensify transiently in the first 2 to 4 weeks at the 7.5 mg maintenance level; typically self-limiting with adequate hydration; probiotics and dietary fibre adjustment may assist symptom management) Vomiting (more commonly reported at higher maintenance dose levels; patients transitioning from 5 mg to 7.5 mg should be counselled to eat slowly, in smaller portions, and to avoid high-fat, high-calorie meals at the time of each weekly injection) Constipation (particularly noted at sustained second-maintenance-level dosing; dietary fibre increase, adequate hydration, and regular physical activity assist bowel regularity) Reduced appetite and early satiety (pharmacodynamically mediated by increased central GLP-1 receptor-driven anorexigenic signalling at 7.5 mg compared with 5 mg; a therapeutically desired effect in the weight management indication; nutritional monitoring is recommended for patients at risk of inadequate micronutrient intake) Abdominal pain, bloating, and dyspepsia (attributable to increased gastric emptying delay at 7.5 mg versus 5 mg; typically mild and transient; self-limiting in most patients within the 4-week adaptation window) Injection site reactions (erythema, pruritus, swelling or mild induration at the injection site; managed by rotating injection sites abdomen, thigh, and upper arm with each weekly dose and avoiding lipohypertrophic or scarred skin areas) Hypoglycaemia (uncommon as tirzepatide 7.5 mg monotherapy due to its glucose-dependent insulin secretagogue mechanism; risk is significantly amplified when combined with insulin or sulfonylureas at the second maintenance dose level; co-medication dose adjustments and self-monitoring intensification are required at every escalation step) Gastro-oesophageal reflux, belching, and flatulence (attributed to increased gastric motility slowing; less frequently reported than nausea or diarrhoea but may persist at sustained 7.5 mg dosing in susceptible patients) |
Serious Warnings and Precautions Thyroid C-cell tumours (medullary thyroid carcinoma risk): tirzepatide caused dose-dependent thyroid C-cell adenomas and carcinomas in rodent chronic dosing studies at systemic exposures relevant to the clinical dose range, including the 7.5 mg dose level. Relevance to human thyroid biology has not been established. Tirzide 7.5 MG is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). All patients maintained on tirzepatide 7.5 mg must be counselled on this theoretical risk and instructed to promptly report any neck mass, dysphagia, persistent hoarseness, or unexplained cervical lymphadenopathy throughout the treatment period at this or any dose level. Pancreatitis: acute pancreatitis including fatal, haemorrhagic, and necrotising cases has been reported with GLP-1 receptor agonists including tirzepatide. If pancreatitis is clinically suspected at the 7.5 mg maintenance dose (new-onset or worsening epigastric pain radiating to the back, nausea, vomiting, elevated serum lipase or amylase), immediately discontinue Tirzide 7.5 MG and perform clinical evaluation including abdominal imaging; do not resume tirzepatide at any dose if pancreatitis is confirmed. Patients with a prior history of pancreatitis require explicit benefit-risk discussion before prescribing or maintaining tirzepatide at the 7.5 mg level. Acute kidney injury (AKI): the increase in GI adverse event frequency and intensity associated with the escalation from 5 mg to 7.5 mg creates an incremental dehydration risk during the early weeks of the second maintenance phase; AKI from volume depletion has been reported with tirzepatide and other incretin-based therapies. Withhold Tirzide 7.5 MG and restore hydration before resuming if clinically significant nausea, vomiting, or diarrhoea occurs; renal function monitoring should be intensified during the first 4 weeks at 7.5 mg in patients with pre-existing CKD or receiving nephrotoxic co-medications. Diabetic retinopathy complications: the incremental HbA1c improvement associated with escalation to 7.5 mg may contribute to further rapid glycaemic normalization in patients already experiencing significant HbA1c reduction from earlier dose levels; ophthalmological monitoring is particularly important during ongoing dose titration in patients with pre-existing proliferative or severe non-proliferative diabetic retinopathy, as continued rapid improvement in glycaemic control may transiently worsen retinopathy. Hypersensitivity reactions: serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with tirzepatide; cases may occur at any dose level, including at the second maintenance dose of 7.5 mg. Permanently discontinue Tirzide 7.5 MG for any confirmed Grade 3 or 4 hypersensitivity reaction and refer urgently to allergy or immunology services as appropriate. Embryo-fetal toxicity: tirzepatide is not recommended during pregnancy. Females of reproductive potential must use effective contraception during Tirzide 7.5 MG treatment and for at least 2 weeks after the final dose. Women using oral hormonal contraceptives must add a barrier contraceptive method for 4 weeks after escalating to the 7.5 mg maintenance dose due to tirzepatide’s gastric-emptying-delay effect on oral contraceptive absorption rate. Breastfeeding is not recommended during treatment. Tirzepatide should be discontinued at least 2 months before a planned pregnancy to allow adequate systemic clearance. |
Who Should Use Tirzide 7.5 MG (Tirzepatide)?
Tirzide 7.5 MG (Tirzepatide) is prescribed for two clearly defined patient groups as specified by the reference-label titration architecture of the tirzepatide prescribing programme.
First, Tirzide 7.5 MG is indicated for adults with type 2 diabetes mellitus or obesity/overweight who have completed ≥4 weeks at the 5 mg first maintenance dose and whose prescribing endocrinologist or diabetologist determines that HbA1c, fasting plasma glucose, or body weight targets have not been fully achieved at 5 mg once weekly the population for whom the 7.5 mg second maintenance dose provides the next incremental step of dual GIP and GLP-1 receptor occupancy to advance toward their individualised therapeutic goal. This escalation decision is guided by HbA1c review at the 4-to-8-week post-initiation visit at 5 mg: patients remaining above their HbA1c target with adequate tolerability are candidates for escalation to Tirzide 7.5 MG.
Second, Tirzide 7.5 MG is indicated for patients already established on tirzepatide 7.5 mg maintenance either as an intermediate step toward higher doses or as their identified long-term minimum effective maintenance dose who require continued once-weekly supply. The reference prescribing information explicitly permits long-term maintenance at 7.5 mg for patients at goal, making Tirzide 7.5 MG an appropriate ongoing prescription for patients who achieve durable HbA1c control or weight management targets without titrating further to 10 mg, 12.5 mg, or 15 mg. Contraindications that must be confirmed absent before prescribing Tirzide 7.5 MG include: personal or family history of MTC or MEN2; type 1 diabetes mellitus; diabetic ketoacidosis; and known hypersensitivity to tirzepatide INN or any product excipient. Baseline and ongoing clinical assessment parameters before and during 7.5 mg maintenance include: HbA1c and fasting glucose (T2DM); BMI and body weight (weight management); renal function (eGFR); blood pressure and cardiovascular risk; diabetic retinopathy status; and concomitant antidiabetic or anticoagulant regimen requiring monitoring. For patients requiring Everest Pharmaceuticals companion medicines or broader diabetes care agents alongside Tirzide 7.5 MG, the Mediaid Pharmacy Everest Pharmaceuticals medicines portfolio and the complete diabetes medicines collection offer a comprehensive selection available for worldwide delivery.
Global Supplier: Mediaid Pharmacy Worldwide Shipping for Tirzide 7.5 MG (Tirzepatide)
Mediaid Pharmacy is a Dhaka-based supplier of specialty and diabetes medicines with worldwide shipping to patients, endocrinology clinics, diabetology centres, hospitals, and distributors across all international markets. Tirzide 7.5 MG (Tirzepatide), manufactured by Everest Pharmaceuticals Ltd. in Bangladesh, is available as 1 pre-filled syringe per box with alcohol pad and first aid bandage and every order is supported by pricing quotations, stock confirmation, product documentation, and full end-to-end international delivery tracking. Endocrinology centres, diabetology clinics, obesity medicine programmes, distributors, and patients can contact the Mediaid Pharmacy team through WhatsApp, phone, or WeChat for all inquiries about Tirzide 7.5 MG Tirzepatide stock, pricing, and delivery timelines to their specific country. Buyers sourcing the complete tirzepatide strength range including Tirzide 2.5 MG initiation, Tirzide 5 MG first maintenance, Tirzide 7.5 MG second maintenance, and higher dose strengths or co-sourcing multiple diabetes and cardiometabolic medicines in a consolidated shipment can browse the complete tirzepatide medicines collection and the broader diabetes medicines collection at Mediaid Pharmacy before requesting a consolidated quotation.
Why Choose Tirzide 7.5 MG (Tirzepatide) from Mediaid Pharmacy?
Tirzide 7.5 MG (Tirzepatide) provides endocrinologists, diabetologists, and obesity medicine specialists with the reference-label second maintenance dose of tirzepatide the 7.5 mg intermediate step that is pharmacokinetically and pharmacodynamically designed to capture meaningful incremental dual GIP/GLP-1 receptor efficacy beyond the 5 mg first maintenance level while protecting patients from the abrupt GI adverse event intensification that a direct 5-to-10 mg dose doubling would produce. The SURPASS Phase 3 programme established that the 5-to-10 mg dose escalation delivers an incremental HbA1c improvement of 0.23 percentage points and 1.7 kg additional body weight reduction in T2DM therapeutic gains that the graduated 7.5 mg step makes accessible with the minimum pharmacological increment, ensuring that every patient who needs more than 5 mg can reach their target in a tolerable, evidence-informed, step-wise manner rather than through dose jumps that may undermine long-term adherence.
Tirzide 7.5 MG is simultaneously a prescribed titration step and a validated long-term maintenance dose a dual clinical role unique to the intermediate doses of the tirzepatide schedule giving prescribers the flexibility to stop titration and maintain patients at 7.5 mg whenever targets are durably met. Tirzide 7.5 MG is manufactured by Everest Pharmaceuticals Ltd. in Bangladesh and supplied in an individually boxed pre-filled syringe with alcohol pad and first aid bandage a complete, no-preparation once-weekly injection kit. Mediaid Pharmacy supplies Tirzide 7.5 MG with full product documentation, specialist supply support, and worldwide shipping from Dhaka for every prescription-based order. To source additional Tirzide strengths, Everest Pharmaceuticals medicines, or a consolidated diabetes medicine panel, visit the Mediaid Pharmacy Everest Pharmaceuticals medicines section and contact the team for a personalised quotation.
Frequently Asked Questions About Tirzide 7.5 MG (Tirzepatide)
What is Tirzide 7.5 MG (Tirzepatide) used for?
Tirzide 7.5 MG (Tirzepatide) is a dual GIP and GLP-1 receptor agonist (twincretin) used as the second maintenance dose of tirzepatide in adults with type 2 diabetes mellitus (T2DM) who require additional glycaemic control beyond what the 5 mg first maintenance dose achieves, and in adults with obesity or overweight with weight-related comorbidities who require additional weight reduction beyond the 5 mg level. Tirzide 7.5 MG is prescribed after ≥4 weeks at 5 mg once weekly and is maintained for ≥4 weeks before any further titration to 10 mg. Patients who achieve their HbA1c or weight management target at 7.5 mg may remain at this dose as a long-term maintenance level without mandatory escalation to higher doses. Tirzide 7.5 MG is available at Mediaid Pharmacy with worldwide shipping.
What is the generic name of Tirzide 7.5 MG?
The generic name of Tirzide 7.5 MG is tirzepatide INN. The product name listed in the Everest Pharmaceuticals Ltd. catalogue is Tirzide. Tirzide 7.5 MG is a solution for injection supplied in a pre-filled syringe (1 syringe/box with alcohol pad and first aid bandage), manufactured by Everest Pharmaceuticals Ltd. in Bangladesh. The originator reference brands for tirzepatide are Mounjaro (for T2DM) and Zepbound (for chronic weight management), developed and commercialised by Eli Lilly and Company. Mediaid Pharmacy distributes Tirzide 7.5 MG globally with worldwide shipping.
How does Tirzide 7.5 MG differ from Tirzide 5 MG and Tirzide 10 MG?
Tirzide 5 MG (Tirzepatide) is the first maintenance dose the level at which full therapeutic efficacy first begins following the 2.5 mg initiation phase. Tirzide 7.5 MG (Tirzepatide) is the second maintenance dose the precisely calibrated intermediate step between 5 mg and 10 mg, providing incremental dual GIP and GLP-1 receptor occupancy that delivers additional glycaemic and weight management benefit for patients whose targets are not fully met at 5 mg, while minimising the GI adverse event risk of a direct 5-to-10 mg dose doubling. Tirzide 10 MG (Tirzepatide) is the third maintenance dose, offering the next clinically evaluated level of tirzepatide efficacy based on SURPASS trial data (–2.24% HbA1c and –9.3 kg weight in SURPASS-2; –19.5% weight reduction in SURMOUNT-1). In the tirzepatide titration ladder, 7.5 mg is the dose that bridges first and third maintenance levels and, for many patients with moderate T2DM or moderate weight management requirements, it may also be the optimal long-term maintenance dose.
When should a patient titrate from 5 mg to 7.5 mg tirzepatide?
The reference prescribing information indicates that a patient should titrate from tirzepatide 5 mg to 7.5 mg after a minimum of 4 weeks at the 5 mg first maintenance dose when their individualised glycaemic target (typically HbA1c below 7.0% for most adults with T2DM per ADA guidelines) or their weight management target has not been achieved and GI tolerability is acceptable. The 4-week minimum at each dose level is required to allow tirzepatide to reach pharmacokinetic steady-state (approximately 4 to 5 half-lives at the 5-day tirzepatide half-life) and for both the prescriber and patient to assess the glycaemic response and GI tolerability before deciding to escalate. If the 5 mg dose is tolerated but HbA1c or weight targets remain unmet at the 4-to-8-week review visit, escalation to Tirzide 7.5 MG is the appropriate reference-label next step. Patients with significant GI intolerance at 5 mg should have their tolerability addressed before escalation is considered; in some cases, extending the 5 mg duration beyond 4 weeks before moving to 7.5 mg is clinically appropriate.
Is 7.5 mg an intermediate titration step or can it be a permanent maintenance dose for tirzepatide?
Tirzepatide 7.5 mg once weekly is both an intermediate titration step and a reference-label-approved long-term maintenance dose. Patients who achieve their HbA1c or weight management goal after ≥4 weeks at 7.5 mg may remain at this dose indefinitely without mandatory further escalation to 10 mg, 12.5 mg, or 15 mg. The reference prescribing information does not require titration beyond any dose level at which therapeutic targets are met. This flexibility allows prescribers to individualize the maintenance dose to the lowest level that achieves and sustains the clinical target minimising GI adverse event burden, reducing ongoing injection-related anxiety, and optimising long-term adherence for patients who do not require the full 15 mg maximum dose to meet their diabetes or weight management goals.
What are the side effects of Tirzide 7.5 MG (Tirzepatide)?
The most common side effects of tirzepatide 7.5 mg are gastrointestinal: nausea (most frequent; more pronounced at 7.5 mg than at 5 mg but substantially mitigated by the prior 4-week adaptation at 5 mg), diarrhoea, vomiting, constipation, decreased appetite, abdominal pain, dyspepsia, belching, and flatulence. GI adverse events are dose-dependent across the tirzepatide range and are most prominent during the first 2 to 4 weeks at each new dose level, diminishing with continued therapy as the GI tract adapts. Injection site reactions (erythema, pruritus, mild swelling) are managed by rotating injection sites with each weekly dose. Hypoglycaemia is uncommon with monotherapy but is significantly amplified by concomitant insulin or sulfonylurea; dose adjustment of co-medications is required at the transition to 7.5 mg. Serious adverse effects include acute pancreatitis, acute kidney injury from dehydration secondary to GI adverse events, hypersensitivity reactions (including anaphylaxis), worsening of diabetic retinopathy with rapid glycaemic normalization, and theoretical thyroid C-cell tumour risk (contraindicated in MTC/MEN2 history patients). Consult your prescribing endocrinologist or diabetologist about your individual risk profile before and throughout Tirzide 7.5 MG treatment.
Is Tirzide 7.5 MG (Tirzepatide) safe during pregnancy or while breastfeeding?
No. Tirzepatide is not recommended during pregnancy at any dose level, including 7.5 mg, due to the potential for fetal harm based on animal reproduction studies and the biological plausibility of embryo-fetal effects from GIP and GLP-1 receptor pathway activation during fetal development. Females of reproductive potential must use effective contraception during Tirzide 7.5 MG treatment and for at least 2 weeks after the final dose. Women using oral hormonal contraceptives must add a barrier method for 4 weeks after the escalation to the 7.5 mg dose level due to tirzepatide-induced gastric emptying delay affecting oral contraceptive absorption. Tirzepatide should be discontinued at least 2 months before a planned pregnancy to allow adequate systemic clearance. Breastfeeding is not recommended during treatment. Discuss all reproductive considerations with your prescribing endocrinologist or obstetrician before starting or continuing Tirzide 7.5 MG.
Can I order Tirzide 7.5 MG (Tirzepatide) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies Tirzide 7.5 MG (Tirzepatide) to patients and healthcare providers globally. Contact Mediaid Pharmacy via WhatsApp, phone, or WeChat at +8801773428128, or email info@mediaidpharmacy.com for pricing, current stock availability, and international delivery details for your country.
Order Tirzide 7.5 MG (Tirzepatide) with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com
Reviews
There are no reviews yet.